We talk to Vellalore Kakkanaiah about his work using flow cytometry in adoptive cell therapy in this interview as part of our author’s perspective series.
An author’s perspective: Amanda King-Ahmad on quantitation of the peptide-1 receptor agonist liraglutide
We talk to Amanda King-Ahmad about her work on the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in this interview as part of our author’s perspective series.
A new molecular engineering method, termed TAC-seq, has been developed to enhance the precision of clinical biomarker analysis.
From the quantification and validation of biomarkers to the integration of novel technology in bioanalytical workflows, as the year comes to a close we’re looking back on the bioanalytical highlights from 2018.
Researchers at the CEU Cardenal Herrera University (Valencia, Spain) have discovered the three most efficient types of salivary biomarkers for the early detection of oral cancer.
Webinar available to view on demand. Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant?
As part of our Spotlight on the validation of biomarkers, we conducted a survey and compared the results to previous data. Find out more about the key trends, challenges and future potential for biomarker R&D in this informative infographic.
In this Spotlight interview, Franklin Spriggs (KCAS; KS, USA) explains his interest in biomarkers and introduces the technologies and techniques utilized and offered by KCAS.
Webinar available to view on demand. In this panel discussion, we hear from key experts in the field about their research and expertise, how they overcome key challenges associated with the technologies they work with and what they envision for the future of biomarker research and validation.
Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.